Andere Sprachen Unity Biotechnology, Inc.

Aktien

A3DWPU

US91381U2006

UBX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 24.04.2024			% 5 Tage	% 1. Jan.
1.47 ^USD	-1.34%		-2.33%	-23.83%

23.04.	Unity Biotechnology, Inc. Verlängerung der klinischen Phase-2b-ASPIREStudie zur Bewertung von UBX1325 bei DME bekannt gegeben	CI
16.04.	UNITY BIOTECHNOLOGY, INC. : HC Wainwright gibt eine Kauf-Bewertung ab	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Unity Biotechnology Adds More Patients, Extends Length of Trial of Prospective Macular Edema Treatment	23.04.
UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME	23.04.
Unity Biotechnology, Inc. Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME	23.04.
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates	15.04.
Unity Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15.04.
Unity Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15.04.
North American Morning Briefing : Stocks Seen -2-	02.04.
North American Morning Briefing : Markets Steady -2-	26.03.
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss	06.02.
Unity Biotechnology, Inc. Announces New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-Lasting, Disease-Modifying Intervention in Vision Loss	06.02.
UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME	12.12.
Unity Biotechnology, Inc. Doses First Patients in Phase 2 Aspire Study of Ubx1325 in DME	12.12.
North American Morning Briefing : Stocks Futures -2-	20.11.
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates	13.11.
Unity Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13.11.
Sector Update: Health Care Stocks Rising Late Afternoon	10.11.
Sector Update: Health Care	10.11.
Unity Biotechnology Agrees to Exercise Warrants for $4.38 Million in Gross Proceeds; Shares Fall	10.11.
UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds	10.11.
UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration	27.09.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Unity Biotechnology, Inc.

Aktien

A3DWPU

US91381U2006

UBX

Andere Sprachen

Filter